董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Julian Gangolli | 男 | Director | 66 | 11.25万美元 | 未持股 | 2024-01-10 |
| Julia A. Haller | 女 | Director | 69 | 7.90万美元 | 未持股 | 2024-01-10 |
| Faisal G. Sukhtian | 男 | Director | 40 | 11.30万美元 | 未持股 | 2024-01-10 |
| Yezan Haddadin | 男 | Director | 48 | 11.00万美元 | 未持股 | 2024-01-10 |
| Gerd Auffarth | 男 | Director | 59 | 7.90万美元 | 未持股 | 2024-01-10 |
| Andong Huang | 男 | Director | 26 | 7.50万美元 | 未持股 | 2024-01-10 |
| C. Russell Trenary III | 男 | President, Chief Executive Officer and Director | 66 | 133.32万美元 | 未持股 | 2024-01-10 |
| Kurt J. Hilzinger | 男 | Director | 63 | 9.50万美元 | 5.23 | 2024-01-10 |
| Lawrence A. Kenyon | 男 | Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director | 59 | 118.43万美元 | 2.59 | 2024-01-10 |
| Ralph H. Thurman | 男 | Executive Chairman of the Board, Director | 74 | 33.67万美元 | 7.99 | 2024-01-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeff Evanson | 男 | Chief Commercial Officer | 56 | 140.90万美元 | 未持股 | 2024-01-10 |
| C. Russell Trenary III | 男 | President, Chief Executive Officer and Director | 66 | 133.32万美元 | 未持股 | 2024-01-10 |
| Lawrence A. Kenyon | 男 | Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director | 59 | 118.43万美元 | 2.59 | 2024-01-10 |
董事简历
中英对照 | 中文 | 英文- Julian Gangolli
-
Julian Gangolli自2020年4月起担任董事会成员。2015年5月至2019年4月，他担任GW Pharmaceuticals股份有限公司北美总裁和GW Phramaceutical Inc.的美国子公司Greenwich Biosciences，Inc.的总裁，在推出其主要治疗候选药物Epidiolex（cannabiiol或CBD）之前，带头建设公司的美国商业基础设施，这对于许多儿童发作的癫痫综合征而言处于晚期发展阶段。2015年7月至2017年3月，Gangolli先生还担任GW Pharmaceuticals股份有限公司董事会成员。在加入GW Pharmaceuticals股份有限公司之前，Gangolli先生曾担任Allergan Inc.北美制药部总裁11年。在此之前，他曾担任Allergan美国眼科护理部高级副总裁。在加入Allergan之前，Gangolli先生曾在英国VIVUS，Inc.、Syntex Pharmaceuticals，Inc.和Ortho-Cilag Pharmacueticals Ltd担任销售和营销职位。Gangolli先生目前担任Krystal Biotech，Inc.和Revance Therapeutics的董事会成员。Gangolli先生拥有金斯顿大学应用化学学士学位。
Julian Gangolli,has served as a member of the Board since April 2020. From May 2015 to April 2019, he served as President, North America of GW Pharmaceuticals Inc., and President of Greenwich Biosciences, Inc., the U.S. subsidiary of GW Pharmaceuticals Inc., where he was responsible for building out the U.S. commercial infrastructure. Mr. Gangolli also served as a member of the board of directors of GW Pharmaceuticals Inc. from July 2015 to March 2017. Prior to joining GW Pharmaceuticals Inc., Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years. Prior to that, he served as Senior Vice President, U.S. Eye Care at Allergan Inc. Prior to Allergan Inc., Mr. Gangolli served in sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the United Kingdom. Mr. Gangolli currently serves as a member of the board of directors of Krystal Biotech, Inc. and Revance Therapeutics. Mr. Gangolli holds a B.S. in Applied Chemistry from Kingston University. - Julian Gangolli自2020年4月起担任董事会成员。2015年5月至2019年4月，他担任GW Pharmaceuticals股份有限公司北美总裁和GW Phramaceutical Inc.的美国子公司Greenwich Biosciences，Inc.的总裁，在推出其主要治疗候选药物Epidiolex（cannabiiol或CBD）之前，带头建设公司的美国商业基础设施，这对于许多儿童发作的癫痫综合征而言处于晚期发展阶段。2015年7月至2017年3月，Gangolli先生还担任GW Pharmaceuticals股份有限公司董事会成员。在加入GW Pharmaceuticals股份有限公司之前，Gangolli先生曾担任Allergan Inc.北美制药部总裁11年。在此之前，他曾担任Allergan美国眼科护理部高级副总裁。在加入Allergan之前，Gangolli先生曾在英国VIVUS，Inc.、Syntex Pharmaceuticals，Inc.和Ortho-Cilag Pharmacueticals Ltd担任销售和营销职位。Gangolli先生目前担任Krystal Biotech，Inc.和Revance Therapeutics的董事会成员。Gangolli先生拥有金斯顿大学应用化学学士学位。
- Julian Gangolli,has served as a member of the Board since April 2020. From May 2015 to April 2019, he served as President, North America of GW Pharmaceuticals Inc., and President of Greenwich Biosciences, Inc., the U.S. subsidiary of GW Pharmaceuticals Inc., where he was responsible for building out the U.S. commercial infrastructure. Mr. Gangolli also served as a member of the board of directors of GW Pharmaceuticals Inc. from July 2015 to March 2017. Prior to joining GW Pharmaceuticals Inc., Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years. Prior to that, he served as Senior Vice President, U.S. Eye Care at Allergan Inc. Prior to Allergan Inc., Mr. Gangolli served in sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the United Kingdom. Mr. Gangolli currently serves as a member of the board of directors of Krystal Biotech, Inc. and Revance Therapeutics. Mr. Gangolli holds a B.S. in Applied Chemistry from Kingston University.
- Julia A. Haller
-
Julia A. Haller ，她于2015年10月入选Servicenow, Inc.董事会，也担任审计委员会的成员。她是the Wills Eye Hospital in Philadelphia, PA 的眼科医生，在那里她担任the William Tasman医学博士讲席教授。她担任托马斯杰弗逊大学的杰弗逊医学院（Jefferson Medical College of Thomas Jefferson University）、Thomas Jefferson University Hospitals的教授和眼科系主席，也是the Wills Vision Research Center at Jefferson的联席董事。她于1986年担任 the Wilmer Eye Institute at Johns Hopkins的第一位女总住院医师，随后任教于Johns Hopkins。她于2002年被誉为首届凯瑟琳 格雷厄姆眼科教授，并于2006年被誉为首届罗伯特·韦尔奇医学眼科学教授。她于2007年担任Wills Eye Hospital的领导。她是世界上最著名的视网膜外科医生和临床医学家，获得大量的学术和职业荣誉和奖励，并发表了300多篇科学论文和书籍章节。她密切参与了许多新的视觉疗法和外科手术的早期开发，并以优异成绩获得了Princeton University的学士学位，以及Harvard Medical School的医学博士学位。她是众多国际科学顾问委员会和数据和安全监测委员会的成员。她是Princeton University的监事会的前任成员，也曾担任Walter Reed Army Medical Center、The Children’s Hospital of Philadelphia的顾问。
Julia A. Haller,has served as a member of the Board since August 2022. Dr. Haller has served as the Ophthalmologist-in-Chief of Wills Eye Hospital since November 2007, where she holds the William Tasman, M.D. Endowed Chair and is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals. Prior to her current positions, Dr. Haller trained at the Wilmer Eye Institute at Johns Hopkins where she served as the first female Chief Resident. She then joined the Johns Hopkins faculty where she directed the retina fellowship program and held the Katharine Graham Chair in Ophthalmology. Dr. Haller currently serves on the board of directors at Bristol Myers Squibb Co. and Opthea Limited and previously served on the board of directors at Eyenovia, Inc. and Celgene. Dr. Haller currently serves on the board of The Philadelphia Orchestra Association, is vice chair of the Board of Trustees of The College of Physicians of Philadelphia, chairs the Heed Ophthalmic Foundation, and is president of the council for the Johns Hopkins Medicine Alumni Association. Dr. Haller received a A.B. in Philosophy from Princeton University and her M.D. from Harvard University Medical School. - Julia A. Haller ，她于2015年10月入选Servicenow, Inc.董事会，也担任审计委员会的成员。她是the Wills Eye Hospital in Philadelphia, PA 的眼科医生，在那里她担任the William Tasman医学博士讲席教授。她担任托马斯杰弗逊大学的杰弗逊医学院（Jefferson Medical College of Thomas Jefferson University）、Thomas Jefferson University Hospitals的教授和眼科系主席，也是the Wills Vision Research Center at Jefferson的联席董事。她于1986年担任 the Wilmer Eye Institute at Johns Hopkins的第一位女总住院医师，随后任教于Johns Hopkins。她于2002年被誉为首届凯瑟琳 格雷厄姆眼科教授，并于2006年被誉为首届罗伯特·韦尔奇医学眼科学教授。她于2007年担任Wills Eye Hospital的领导。她是世界上最著名的视网膜外科医生和临床医学家，获得大量的学术和职业荣誉和奖励，并发表了300多篇科学论文和书籍章节。她密切参与了许多新的视觉疗法和外科手术的早期开发，并以优异成绩获得了Princeton University的学士学位，以及Harvard Medical School的医学博士学位。她是众多国际科学顾问委员会和数据和安全监测委员会的成员。她是Princeton University的监事会的前任成员，也曾担任Walter Reed Army Medical Center、The Children’s Hospital of Philadelphia的顾问。
- Julia A. Haller,has served as a member of the Board since August 2022. Dr. Haller has served as the Ophthalmologist-in-Chief of Wills Eye Hospital since November 2007, where she holds the William Tasman, M.D. Endowed Chair and is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals. Prior to her current positions, Dr. Haller trained at the Wilmer Eye Institute at Johns Hopkins where she served as the first female Chief Resident. She then joined the Johns Hopkins faculty where she directed the retina fellowship program and held the Katharine Graham Chair in Ophthalmology. Dr. Haller currently serves on the board of directors at Bristol Myers Squibb Co. and Opthea Limited and previously served on the board of directors at Eyenovia, Inc. and Celgene. Dr. Haller currently serves on the board of The Philadelphia Orchestra Association, is vice chair of the Board of Trustees of The College of Physicians of Philadelphia, chairs the Heed Ophthalmic Foundation, and is president of the council for the Johns Hopkins Medicine Alumni Association. Dr. Haller received a A.B. in Philosophy from Princeton University and her M.D. from Harvard University Medical School.
- Faisal G. Sukhtian
-
FaisalG.Sukhtian自2017年9月以来一直担任我们的董事会成员。Sukhtian先生自2011年起担任Biolexis的董事，自2008年起担任多元化投资公司GMS Holdings的执行董事。除了管理GMS Holdings的运营外，Sukhtian先生还监督GMS Holdings投资组合中的多项投资，并担任GMS Holdings’；董事会董事。Sukhtian从2008年到2011年担任Munir Sukhtian International执行董事。从2010年到2011年，他曾担任Agri Sciences公司（位于土耳其的农用化学品制造企业）的董事总经理。Sukhtian自2008年起担任Expert Petroleum（一家位于罗马尼亚的油田服务公司）董事会成员，自2010年起担任Agri Sciences MS Pharma（一家领先的MENA品牌仿制药公司）董事会成员，自2011年起担任Stelis Biopharma Private Limited董事会成员，自2015年以来，是一家位于印度的生物治疗和生物仿制药开发商和制造商。Sukhtian先生此前曾于2008年至2014年担任总部位于美国的跨国仿制药公司Alvogen的董事会成员，并于2015年至2017年担任总部位于美国的工具存储制造商Waterloo Industries，Inc.的董事会成员。加入GMS Holdings公司之前，他曾任职JP Morgan公司（位于纽约），在那里他主要从事并购、债务和股权交易，为工业和运输行业的客户服务。Sukhtian先生在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在乔治敦大学（Georgetown University）外交学院（School of Foreign Service）获得国际经济学学士学位。Sukhtian先生最初被任命填补我们董事会的空缺，并根据Biolexis IRA被Biolexis指定填补该空缺。
Faisal G. Sukhtian,has served as a member of the Board since September 2017. Mr. Sukhtian is the Executive Director at GMS Holdings, a privately owned diversified investment company. Mr. Sukhtian oversees a number of investments within the GMS Holdings portfolio and has served as a director on the company's board since 2008. Mr. Sukhtian has extensive experience in operations, strategy development and mergers and acquisitions in the biopharma and life sciences space. He has been the chairman of the board of Genepharm, a leading European B2B pharmaceutical company, since 2019. Mr. Sukhtian served as a member of the board of MS Pharma, a leading regional pharmaceutical company focused on the MENA region, since 2011. Mr. Sukhtian has served as Vice Chairman of the board of Agri Sciences, an international crop protection company headquartered in Jordan, since 2010. Mr. Sukhtian previously served on the boards of Stelis Biopharma, a biotech company based in India, from 2015 to 2021, as well as Alvogen, a global generics company, from 2008 to 2014. From 2008 to 2011, Mr. Sukhtian served as Executive Director of Munir Sukhtian International. Mr. Sukhtian has served as a member of the board of directors of Expert Petroleum, an oilfield services company based in Romania, since 2008, and Waterloo Industries, Inc., a manufacturer of tool storage based in the United States, from 2015 to 2017. Prior to joining GMS Holdings, Mr. Sukhtian worked at J.P. Morgan, in New York, where he worked primarily on mergers and acquisitions, debt and equity transactions serving clients in the industrials and transportation industries. Mr. Sukhtian received an M.B.A. from Columbia Business School and a B.S. in International Economics from Georgetown University's School of Foreign Service. Mr. Sukhtian is designated to the Board by GMS Ventures pursuant to the Amended and Restated Investor Rights Agreement by and between the Company and GMS Ventures dated April 21, 2022. - FaisalG.Sukhtian自2017年9月以来一直担任我们的董事会成员。Sukhtian先生自2011年起担任Biolexis的董事，自2008年起担任多元化投资公司GMS Holdings的执行董事。除了管理GMS Holdings的运营外，Sukhtian先生还监督GMS Holdings投资组合中的多项投资，并担任GMS Holdings’；董事会董事。Sukhtian从2008年到2011年担任Munir Sukhtian International执行董事。从2010年到2011年，他曾担任Agri Sciences公司（位于土耳其的农用化学品制造企业）的董事总经理。Sukhtian自2008年起担任Expert Petroleum（一家位于罗马尼亚的油田服务公司）董事会成员，自2010年起担任Agri Sciences MS Pharma（一家领先的MENA品牌仿制药公司）董事会成员，自2011年起担任Stelis Biopharma Private Limited董事会成员，自2015年以来，是一家位于印度的生物治疗和生物仿制药开发商和制造商。Sukhtian先生此前曾于2008年至2014年担任总部位于美国的跨国仿制药公司Alvogen的董事会成员，并于2015年至2017年担任总部位于美国的工具存储制造商Waterloo Industries，Inc.的董事会成员。加入GMS Holdings公司之前，他曾任职JP Morgan公司（位于纽约），在那里他主要从事并购、债务和股权交易，为工业和运输行业的客户服务。Sukhtian先生在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在乔治敦大学（Georgetown University）外交学院（School of Foreign Service）获得国际经济学学士学位。Sukhtian先生最初被任命填补我们董事会的空缺，并根据Biolexis IRA被Biolexis指定填补该空缺。
- Faisal G. Sukhtian,has served as a member of the Board since September 2017. Mr. Sukhtian is the Executive Director at GMS Holdings, a privately owned diversified investment company. Mr. Sukhtian oversees a number of investments within the GMS Holdings portfolio and has served as a director on the company's board since 2008. Mr. Sukhtian has extensive experience in operations, strategy development and mergers and acquisitions in the biopharma and life sciences space. He has been the chairman of the board of Genepharm, a leading European B2B pharmaceutical company, since 2019. Mr. Sukhtian served as a member of the board of MS Pharma, a leading regional pharmaceutical company focused on the MENA region, since 2011. Mr. Sukhtian has served as Vice Chairman of the board of Agri Sciences, an international crop protection company headquartered in Jordan, since 2010. Mr. Sukhtian previously served on the boards of Stelis Biopharma, a biotech company based in India, from 2015 to 2021, as well as Alvogen, a global generics company, from 2008 to 2014. From 2008 to 2011, Mr. Sukhtian served as Executive Director of Munir Sukhtian International. Mr. Sukhtian has served as a member of the board of directors of Expert Petroleum, an oilfield services company based in Romania, since 2008, and Waterloo Industries, Inc., a manufacturer of tool storage based in the United States, from 2015 to 2017. Prior to joining GMS Holdings, Mr. Sukhtian worked at J.P. Morgan, in New York, where he worked primarily on mergers and acquisitions, debt and equity transactions serving clients in the industrials and transportation industries. Mr. Sukhtian received an M.B.A. from Columbia Business School and a B.S. in International Economics from Georgetown University's School of Foreign Service. Mr. Sukhtian is designated to the Board by GMS Ventures pursuant to the Amended and Restated Investor Rights Agreement by and between the Company and GMS Ventures dated April 21, 2022.
- Yezan Haddadin
-
Yezan Haddadin自2017年10月以来一直担任我们的董事会成员。自2017年7月以来，Haddadin先生一直担任GMS Capital Partners LLC（一家投资公司，专注于在北美进行直接私募股权投资）的首席执行官。GMS Capital Partners LLC是GMS Holdings的子公司。2014年至2017年，Haddadin先生担任位于约旦安曼和阿拉伯联合酋长国迪拜的区域投资银行的首席执行官兼董事会成员。从2013年到2014年，Haddadin先生担任Ripplewood Holdings LLC的顾问，该公司是一家位于纽约的私募股权公司。Haddadin先生还于2007年至2013年担任纽约Perella Weinberg Partners的董事总经理，并于2000年至2007年担任J.P.Morgan并购集团的执行董事。Haddadin先生拥有西北大学法学院（Northwestern University Law School）法学博士学位和乔治敦大学（Georgetown University）外交服务学士学位。Haddadin先生最初被任命填补董事会的空缺，并由Biolexis Pte.Ltd.或Biolexis根据本公司与Biolexis于2017年9月11日签订并不时修订的《投资者权利协议》指定填补该空缺，或者Biolexis IRA。
Yezan Haddadin,has served as a member of the Board since October 2017. Since July 2017, Mr. Haddadin has served as chief executive officer of GMS Capital Partners LLC, an investment company focused on making direct private equity investments in North America. GMS Capital Partners LLC is a subsidiary of GMS Holdings. From 2014 to 2017, Mr. Haddadin served as the Chief Executive Officer and a member of the board of directors of a regional investment bank based in Amman, Jordan and Dubai, United Arab Emirates. From 2013 to 2014, Mr. Haddadin served as an Advisor at Ripplewood Holdings LLC, a New York-based private equity firm. Mr. Haddadin also served as a Managing Director at Perella Weinberg Partners in New York from 2007 to 2013 and an Executive Director with J.P. Morgan in its mergers and acquisitions group from 2000 to 2007. Mr. Haddadin is member of the board of directors of Jordan Ahli Bank. Mr. Haddadin previously served as a member of the board of directors at Sixth of October Development & Investment Company, a publicly listed Egyptian real estate development company. Mr. Haddadin holds a J.D. from Northwestern University Law School and a B.S. in Foreign Service from Georgetown University. Mr. Haddadin is designated to the Board by GMS Ventures & Investments, or GMS Ventures, pursuant to the Amended and Restated Investor Rights Agreement by and between the Company and GMS Ventures dated April 21, 2022. - Yezan Haddadin自2017年10月以来一直担任我们的董事会成员。自2017年7月以来，Haddadin先生一直担任GMS Capital Partners LLC（一家投资公司，专注于在北美进行直接私募股权投资）的首席执行官。GMS Capital Partners LLC是GMS Holdings的子公司。2014年至2017年，Haddadin先生担任位于约旦安曼和阿拉伯联合酋长国迪拜的区域投资银行的首席执行官兼董事会成员。从2013年到2014年，Haddadin先生担任Ripplewood Holdings LLC的顾问，该公司是一家位于纽约的私募股权公司。Haddadin先生还于2007年至2013年担任纽约Perella Weinberg Partners的董事总经理，并于2000年至2007年担任J.P.Morgan并购集团的执行董事。Haddadin先生拥有西北大学法学院（Northwestern University Law School）法学博士学位和乔治敦大学（Georgetown University）外交服务学士学位。Haddadin先生最初被任命填补董事会的空缺，并由Biolexis Pte.Ltd.或Biolexis根据本公司与Biolexis于2017年9月11日签订并不时修订的《投资者权利协议》指定填补该空缺，或者Biolexis IRA。
- Yezan Haddadin,has served as a member of the Board since October 2017. Since July 2017, Mr. Haddadin has served as chief executive officer of GMS Capital Partners LLC, an investment company focused on making direct private equity investments in North America. GMS Capital Partners LLC is a subsidiary of GMS Holdings. From 2014 to 2017, Mr. Haddadin served as the Chief Executive Officer and a member of the board of directors of a regional investment bank based in Amman, Jordan and Dubai, United Arab Emirates. From 2013 to 2014, Mr. Haddadin served as an Advisor at Ripplewood Holdings LLC, a New York-based private equity firm. Mr. Haddadin also served as a Managing Director at Perella Weinberg Partners in New York from 2007 to 2013 and an Executive Director with J.P. Morgan in its mergers and acquisitions group from 2000 to 2007. Mr. Haddadin is member of the board of directors of Jordan Ahli Bank. Mr. Haddadin previously served as a member of the board of directors at Sixth of October Development & Investment Company, a publicly listed Egyptian real estate development company. Mr. Haddadin holds a J.D. from Northwestern University Law School and a B.S. in Foreign Service from Georgetown University. Mr. Haddadin is designated to the Board by GMS Ventures & Investments, or GMS Ventures, pursuant to the Amended and Restated Investor Rights Agreement by and between the Company and GMS Ventures dated April 21, 2022.
- Gerd Auffarth
-
Gerd Auffarth自2020年4月起担任我们的董事会成员。Auffarth教授是一位国际公认的眼科医生，在研究与开发和患者的临床护理领域工作。他目前担任Heidelberg University Eye Clinic的医学董事。2011年被任命为医学主任之前，他曾担任the University Eye Clinic的高级医生。他目前担任International Vision Correction Research Center IVCRC和the David J.Apple Laboratory for Ocular Pathology的董事。他是the German and the European Society for Cataract and Refractive Surgery的董事会成员。2004年，他被任命为海德堡眼科副主席和副主任；2005年5月，他被授予海德堡大学医学院特聘教授职位。Auffarth博士持有RWTH Aachen University的医学博士学位和the Ruprecht-Karls University of Heidelberg的眼部病理学博士学位。
Gerd Auffarth,has served as a member of the Board since April 2020. Prof. Dr. Auffarth is an internationally recognized ophthalmologist in the area of research and development as well as clinical care for patients. He currently serves as the Medical Director of Heidelberg University Eye Clinic. Prior to his appointment as Medical Director in 2011, he worked as a senior physician at the University Eye Clinic. He currently serves as the Director of the International Vision Correction Research Center (IVCRC) and the David J. Apple Laboratory for Ocular Pathology. He is a board member of the German and the European Society for Cataract and Refractive Surgery. In 2004 he was appointed Vice Chairman and Deputy Director of the Heidelberg Department of Ophthalmology; he was awarded Extraordinary Professorship in the Medical Faculty of the University of Heidelberg in May 2005. Prof. Dr. Auffarth holds an M.D. from RWTH Aachen University and a Ph.D. in Ocular Pathology from the Ruprecht-Karls University of Heidelberg. - Gerd Auffarth自2020年4月起担任我们的董事会成员。Auffarth教授是一位国际公认的眼科医生，在研究与开发和患者的临床护理领域工作。他目前担任Heidelberg University Eye Clinic的医学董事。2011年被任命为医学主任之前，他曾担任the University Eye Clinic的高级医生。他目前担任International Vision Correction Research Center IVCRC和the David J.Apple Laboratory for Ocular Pathology的董事。他是the German and the European Society for Cataract and Refractive Surgery的董事会成员。2004年，他被任命为海德堡眼科副主席和副主任；2005年5月，他被授予海德堡大学医学院特聘教授职位。Auffarth博士持有RWTH Aachen University的医学博士学位和the Ruprecht-Karls University of Heidelberg的眼部病理学博士学位。
- Gerd Auffarth,has served as a member of the Board since April 2020. Prof. Dr. Auffarth is an internationally recognized ophthalmologist in the area of research and development as well as clinical care for patients. He currently serves as the Medical Director of Heidelberg University Eye Clinic. Prior to his appointment as Medical Director in 2011, he worked as a senior physician at the University Eye Clinic. He currently serves as the Director of the International Vision Correction Research Center (IVCRC) and the David J. Apple Laboratory for Ocular Pathology. He is a board member of the German and the European Society for Cataract and Refractive Surgery. In 2004 he was appointed Vice Chairman and Deputy Director of the Heidelberg Department of Ophthalmology; he was awarded Extraordinary Professorship in the Medical Faculty of the University of Heidelberg in May 2005. Prof. Dr. Auffarth holds an M.D. from RWTH Aachen University and a Ph.D. in Ocular Pathology from the Ruprecht-Karls University of Heidelberg.
- Andong Huang
-
黄安东自2020年6月起担任我们的董事会成员。黄先生自2017年以来一直担任Syntone Technologies Group China业务发展Vice President，专注于战略合作伙伴关系和国际业务关系。黄先生精通普通话和英语，并正在多伦多大学（University of Toronto）完成经济学和东亚研究专业的文学和理学学士学位（预计2021年6月）。Huang先生目前担任多伦多大学（University of Toronto）中国本科生协会主席，该机构是该机构最大的学生组织之一。黄先生最初由Syntone Ventures LLC根据2020年5月22日公司与Syntone Ventures LLC之间的股票购买协议任命为董事会成员。
Andong Huang,has served as a member of the Board since June 2020. Mr. Huang has been Vice President, Business Development for Syntone Technologies Group (China) since 2017, focusing on strategic partnerships and international business relationships. Mr. Huang received his Honours Bachelor of Arts from the University of Toronto with majors in Economics and East Asian Studies and is fluent in Mandarin Chinese and English. Mr. Huang was initially appointed to the Board by Syntone Ventures LLC pursuant to the Stock Purchase Agreement by and between the Company and Syntone Ventures LLC, dated May 22, 2020. - 黄安东自2020年6月起担任我们的董事会成员。黄先生自2017年以来一直担任Syntone Technologies Group China业务发展Vice President，专注于战略合作伙伴关系和国际业务关系。黄先生精通普通话和英语，并正在多伦多大学（University of Toronto）完成经济学和东亚研究专业的文学和理学学士学位（预计2021年6月）。Huang先生目前担任多伦多大学（University of Toronto）中国本科生协会主席，该机构是该机构最大的学生组织之一。黄先生最初由Syntone Ventures LLC根据2020年5月22日公司与Syntone Ventures LLC之间的股票购买协议任命为董事会成员。
- Andong Huang,has served as a member of the Board since June 2020. Mr. Huang has been Vice President, Business Development for Syntone Technologies Group (China) since 2017, focusing on strategic partnerships and international business relationships. Mr. Huang received his Honours Bachelor of Arts from the University of Toronto with majors in Economics and East Asian Studies and is fluent in Mandarin Chinese and English. Mr. Huang was initially appointed to the Board by Syntone Ventures LLC pursuant to the Stock Purchase Agreement by and between the Company and Syntone Ventures LLC, dated May 22, 2020.
- C. Russell Trenary III
-
C. Russell Trenary III，自2021年7月起担任Outlook Therapeutics, Inc.总裁、首席执行官兼董事会成员。他最近于2020年4月至2021年7月担任InnFocus Inc.的执行顾问，2013年10月至2020年4月担任总裁兼首席执行官，包括2016年8月参天制药收购该公司。在此之前，他曾担任全球医疗器械公司G & H Orthodontics的总裁兼首席执行官，并在Advanced Medical Optics（AMO），Inc.担任过多个高级领导职位，包括白内障业务部总裁、首席营销官、美洲区总裁、公共政策执行副总裁。在此之前，Trenary先生曾在Sunrise Technologies International，Inc.担任高管职务，曾在VidaMed，Inc.担任全球销售与营销高级副总裁/官员，并在Allergan，Inc.担任过多个高级领导职务，包括高级副总裁和医学光学事业部总经理。在他的职业生涯中，他在七项收购中发挥了关键作用，并密切领导了眼部护理医疗设备领域的四项主要产品发布。Trenary先生在俄亥俄州牛津迈阿密大学获得工商管理学士学位，在密歇根州立大学获得工商管理硕士学位。
C. Russell Trenary III,has served as Outlook Therapeutics, Inc. President, Chief Executive Officer, and member of the Board of Directors, or the Board, since July 2021. He most recently was an Executive Advisor at InnFocus Inc. from April 2020 to July 2021, after serving as President & CEO from October 2013 to April 2020, including during the company's acquisition in August 2016 by Santen Pharmaceutical Co., Ltd. Prior to that, he was President and CEO of G&H Orthodontics, a global medical device company, and served in a number of senior leadership positions at Advanced Medical Optics, Inc., including as President of the cataract business unit, Chief Marketing Officer, President Americas, Executive VP Public Policy. Prior to that, Mr. Trenary held C-suite positions at Sunrise Technologies International, Inc., served as Senior Vice President, Worldwide Sales & Marketing / Officer at VidaMed, Inc. and held several senior leadership roles at Allergan, Inc., including as Senior Vice President and General Manager of the Medical Optics business unit. Over the course of his career, he has played a key role in seven acquisitions and closely led four major product launches in eye care medical devices. Mr. Trenary received a B.S. in Business Administration from Miami University, Oxford, OH and his MBA from Michigan State University. - C. Russell Trenary III，自2021年7月起担任Outlook Therapeutics, Inc.总裁、首席执行官兼董事会成员。他最近于2020年4月至2021年7月担任InnFocus Inc.的执行顾问，2013年10月至2020年4月担任总裁兼首席执行官，包括2016年8月参天制药收购该公司。在此之前，他曾担任全球医疗器械公司G & H Orthodontics的总裁兼首席执行官，并在Advanced Medical Optics（AMO），Inc.担任过多个高级领导职位，包括白内障业务部总裁、首席营销官、美洲区总裁、公共政策执行副总裁。在此之前，Trenary先生曾在Sunrise Technologies International，Inc.担任高管职务，曾在VidaMed，Inc.担任全球销售与营销高级副总裁/官员，并在Allergan，Inc.担任过多个高级领导职务，包括高级副总裁和医学光学事业部总经理。在他的职业生涯中，他在七项收购中发挥了关键作用，并密切领导了眼部护理医疗设备领域的四项主要产品发布。Trenary先生在俄亥俄州牛津迈阿密大学获得工商管理学士学位，在密歇根州立大学获得工商管理硕士学位。
- C. Russell Trenary III,has served as Outlook Therapeutics, Inc. President, Chief Executive Officer, and member of the Board of Directors, or the Board, since July 2021. He most recently was an Executive Advisor at InnFocus Inc. from April 2020 to July 2021, after serving as President & CEO from October 2013 to April 2020, including during the company's acquisition in August 2016 by Santen Pharmaceutical Co., Ltd. Prior to that, he was President and CEO of G&H Orthodontics, a global medical device company, and served in a number of senior leadership positions at Advanced Medical Optics, Inc., including as President of the cataract business unit, Chief Marketing Officer, President Americas, Executive VP Public Policy. Prior to that, Mr. Trenary held C-suite positions at Sunrise Technologies International, Inc., served as Senior Vice President, Worldwide Sales & Marketing / Officer at VidaMed, Inc. and held several senior leadership roles at Allergan, Inc., including as Senior Vice President and General Manager of the Medical Optics business unit. Over the course of his career, he has played a key role in seven acquisitions and closely led four major product launches in eye care medical devices. Mr. Trenary received a B.S. in Business Administration from Miami University, Oxford, OH and his MBA from Michigan State University.
- Kurt J. Hilzinger
-
Kurt J. Hilzinger，于2003年7月，他最初选入董事会，并当选为董事会主席在2014年1月1日起生效。自2010年8月直至其获委任为主席，他担任首席董事。他是法院广场资本合伙有限公司的合伙人，并在自2007年11月起就担任此职务。在此之前，自2004年3月至2007年11月，他是美源伯根公司的董事；2002年10月至2007年11月，是美源伯根公司总裁和首席营运官；2001年8月至2002年10月，担任美源伯根公司的执行副总裁兼首席营运官。
Kurt J. Hilzinger,was initially elected to the Board in July 2003, and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from August 2010 until his appointment as Chairman. Mr. Hilzinger is a Partner at Court Square Capital Partners, an independent private equity firm, having held this position since November 2007. At Court Square, Mr. Hilzinger focuses principally on investments in the healthcare industry. Prior to that, he was a Director of AmerisourceBergen Corporation from March 2004 to November 2007; having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002. Mr. Hilzinger also serves on the Board of Directors of Outlook Therapeutics, Inc. and several privately held companies. - Kurt J. Hilzinger，于2003年7月，他最初选入董事会，并当选为董事会主席在2014年1月1日起生效。自2010年8月直至其获委任为主席，他担任首席董事。他是法院广场资本合伙有限公司的合伙人，并在自2007年11月起就担任此职务。在此之前，自2004年3月至2007年11月，他是美源伯根公司的董事；2002年10月至2007年11月，是美源伯根公司总裁和首席营运官；2001年8月至2002年10月，担任美源伯根公司的执行副总裁兼首席营运官。
- Kurt J. Hilzinger,was initially elected to the Board in July 2003, and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from August 2010 until his appointment as Chairman. Mr. Hilzinger is a Partner at Court Square Capital Partners, an independent private equity firm, having held this position since November 2007. At Court Square, Mr. Hilzinger focuses principally on investments in the healthcare industry. Prior to that, he was a Director of AmerisourceBergen Corporation from March 2004 to November 2007; having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002. Mr. Hilzinger also serves on the Board of Directors of Outlook Therapeutics, Inc. and several privately held companies.
- Lawrence A. Kenyon
-
Lawrence A. Kenyon，2018年8月起担任Outlook Therapeutics, Inc.董事会成员兼首席财务官，2018年8月至2021年7月担任首席执行官兼总裁，2018年6月至2018年8月担任临时首席执行官，2015年9月起担任Outlook Therapeutics, Inc.的首席财务官、财务主管兼公司秘书。在此之前，2014年2月至2015年9月，Kenyon先生担任Arno Therapeutics，Inc.的首席财务官，该公司是一家生物制药公司，专注于开发治疗癌症和其他危及生命的疾病的药物，并于2014年7月至2015年9月担任首席运营官。2011年12月至2013年3月，Kenyon先生担任Tamir Biotechnology，Inc.的临时总裁兼首席执行官、首席财务官兼秘书。Tamir Biotechnology是一家上市的生物制药公司，从事肿瘤学和抗感染疗法的开发。在此之前，2008年12月至2010年7月，Kenyon先生担任Par Pharmaceutical Companies，Inc.（一家上市的仿制药和品牌专业制药公司）财务执行副总裁，并于2009年3月起担任首席财务官。在加入Par公司之前，Kenyon先生于2007年1月至2009年2月担任Alfacell公司（简称Alfacell）的首席财务官兼秘书。在此期间，他还担任过Alfacell公司执行副总裁、首席运营官兼总裁等职务，并于2007年11月至2009年4月担任Alfacell公司董事会成员。在加入Alfacell公司之前，Kenyon先生于2000年至2006年在NeoPharm公司（一家上市的生物制药公司）担任执行副总裁、首席财务官和公司秘书。Kenyon先生在University of Wisconsin—Whitewater获得会计学学士学位，是伊利诺伊州的注册会计师。
Lawrence A. Kenyon,has served as a member of Outlook Therapeutics, Inc. Board and Chief Financial Officer since August 2018, as Chief Executive Officer and President from August 2018 to July 2021, as Interim Chief Executive Officer from June 2018 to August 2018, and as Outlook Therapeutics, Inc. Chief Financial Officer, Treasurer and Corporate Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company. Prior to March 2009, Mr. Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, from January 2007 through February 2009 and also served at various times during this period as Alfacell's Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell's board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006. Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin—Whitewater and is a Certified Public Accountant in Illinois. - Lawrence A. Kenyon，2018年8月起担任Outlook Therapeutics, Inc.董事会成员兼首席财务官，2018年8月至2021年7月担任首席执行官兼总裁，2018年6月至2018年8月担任临时首席执行官，2015年9月起担任Outlook Therapeutics, Inc.的首席财务官、财务主管兼公司秘书。在此之前，2014年2月至2015年9月，Kenyon先生担任Arno Therapeutics，Inc.的首席财务官，该公司是一家生物制药公司，专注于开发治疗癌症和其他危及生命的疾病的药物，并于2014年7月至2015年9月担任首席运营官。2011年12月至2013年3月，Kenyon先生担任Tamir Biotechnology，Inc.的临时总裁兼首席执行官、首席财务官兼秘书。Tamir Biotechnology是一家上市的生物制药公司，从事肿瘤学和抗感染疗法的开发。在此之前，2008年12月至2010年7月，Kenyon先生担任Par Pharmaceutical Companies，Inc.（一家上市的仿制药和品牌专业制药公司）财务执行副总裁，并于2009年3月起担任首席财务官。在加入Par公司之前，Kenyon先生于2007年1月至2009年2月担任Alfacell公司（简称Alfacell）的首席财务官兼秘书。在此期间，他还担任过Alfacell公司执行副总裁、首席运营官兼总裁等职务，并于2007年11月至2009年4月担任Alfacell公司董事会成员。在加入Alfacell公司之前，Kenyon先生于2000年至2006年在NeoPharm公司（一家上市的生物制药公司）担任执行副总裁、首席财务官和公司秘书。Kenyon先生在University of Wisconsin—Whitewater获得会计学学士学位，是伊利诺伊州的注册会计师。
- Lawrence A. Kenyon,has served as a member of Outlook Therapeutics, Inc. Board and Chief Financial Officer since August 2018, as Chief Executive Officer and President from August 2018 to July 2021, as Interim Chief Executive Officer from June 2018 to August 2018, and as Outlook Therapeutics, Inc. Chief Financial Officer, Treasurer and Corporate Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company. Prior to March 2009, Mr. Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, from January 2007 through February 2009 and also served at various times during this period as Alfacell's Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell's board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006. Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin—Whitewater and is a Certified Public Accountant in Illinois.
- Ralph H. Thurman
-
Ralph H. Thurman，2012年6月被选为公司董事。目前，他在一家私人股本公司担任高ijguwenhe运营执行官。从2008年到2011年，他在CardioNet公司担任执行董事长，从2009年到2010年，他担任该公司临时首席执行官。从2001年到2007年，他担任VIASYS健康保健公司（VIASYS Healthcare Inc.）担任创始人、董事长和首席执行官，这是一家多元健康保健将科技公司。 2007年，VIASYS 公司被Cardinal健康保健公司（Cardinal Healthcare Inc.）收购，2008年，他在Cardinal健康保健公司（Cardinal Healthcare Inc.）担任咨询师。从1997年到2001年，他担任Strategic Reserves公司董事长和首席执行官，这是一家向生物制药、基因和医疗器材公司提供顾问服务的公司。从1993年到1997年，他在Corning Life Sciences公司担任董事长和首席执行官，从1984年到1993年，他担任Rhone-Poulenc Rorer制药公司（Rhone-Poulenc Rorer Pharmaceuticals, Inc.）多个职位，这是一家全球制药公司，最后他担任该公司总裁。目前，他在Presbia公司担任执行董事长，这是一家私人医疗器材公司，也是Arno Therapeutics公司副董事长，这是一家上市的生物制药公司。之前，他在Enzon公司担任董事长，这是一家上市生物科技公司，也是多家上市和私人公司的董事。
Ralph H. Thurman,has served as the Executive Chairman of the Board since June 2018 and has served as a member of the Board since April 2018. He also currently serves as a director of uMethod Inc, and as an Advisory Board Director for the Villanova Law School Scarpa Center for Law and Entrepreneurialism and is engaged as an independent advisor/operating executive in the private equity industry. Mr. Thurman was previously a member of the board of directors of Allscripts, Inc. and the Executive Chairman of Presbia PLC (an Orchard Capital Corporation company), a publicly-traded medical device company. From 2008 to 2011, Mr. Thurman served as Executive Chairman of CardioNet Inc. (now known as BioTelemetry, Inc.), and as its interim Chief Executive Officer from 2008 until 2010. From 2001 until 2007, Mr. Thurman was Founder, Chairman and Chief Executive Officer of VIASYS Healthcare Inc., a diversified healthcare technology company, which was acquired by Cardinal Healthcare Inc. in 2007. Mr. Thurman served as a consultant to Cardinal Healthcare Inc. from the date of acquisition until 2008. From 1997 until 2001, Mr. Thurman served as Chairman and Chief Executive Officer of Strategic Reserves LLC, which provided advisory services to bio-pharmaceutical, genomic and medical device companies. From 1993 until 1997, Mr. Thurman was Chairman and Chief Executive Officer of Corning Life Sciences, Inc., and from 1984 until 1993, Mr. Thurman held various positions at Rhone-Poulenc Rorer Pharmaceuticals, Inc., a global pharmaceutical company, ultimately as its President. Mr. Thurman served as a fighter pilot in the United States Air Force, is a member of the Distinguished Flying Cross Society of America and graduated from the USAF Air Command and Staff College. Mr. Thurman holds a B.S. in Economics from Virginia Polytechnic Institute and an M.A. in Management from Webster University. - Ralph H. Thurman，2012年6月被选为公司董事。目前，他在一家私人股本公司担任高ijguwenhe运营执行官。从2008年到2011年，他在CardioNet公司担任执行董事长，从2009年到2010年，他担任该公司临时首席执行官。从2001年到2007年，他担任VIASYS健康保健公司（VIASYS Healthcare Inc.）担任创始人、董事长和首席执行官，这是一家多元健康保健将科技公司。 2007年，VIASYS 公司被Cardinal健康保健公司（Cardinal Healthcare Inc.）收购，2008年，他在Cardinal健康保健公司（Cardinal Healthcare Inc.）担任咨询师。从1997年到2001年，他担任Strategic Reserves公司董事长和首席执行官，这是一家向生物制药、基因和医疗器材公司提供顾问服务的公司。从1993年到1997年，他在Corning Life Sciences公司担任董事长和首席执行官，从1984年到1993年，他担任Rhone-Poulenc Rorer制药公司（Rhone-Poulenc Rorer Pharmaceuticals, Inc.）多个职位，这是一家全球制药公司，最后他担任该公司总裁。目前，他在Presbia公司担任执行董事长，这是一家私人医疗器材公司，也是Arno Therapeutics公司副董事长，这是一家上市的生物制药公司。之前，他在Enzon公司担任董事长，这是一家上市生物科技公司，也是多家上市和私人公司的董事。
- Ralph H. Thurman,has served as the Executive Chairman of the Board since June 2018 and has served as a member of the Board since April 2018. He also currently serves as a director of uMethod Inc, and as an Advisory Board Director for the Villanova Law School Scarpa Center for Law and Entrepreneurialism and is engaged as an independent advisor/operating executive in the private equity industry. Mr. Thurman was previously a member of the board of directors of Allscripts, Inc. and the Executive Chairman of Presbia PLC (an Orchard Capital Corporation company), a publicly-traded medical device company. From 2008 to 2011, Mr. Thurman served as Executive Chairman of CardioNet Inc. (now known as BioTelemetry, Inc.), and as its interim Chief Executive Officer from 2008 until 2010. From 2001 until 2007, Mr. Thurman was Founder, Chairman and Chief Executive Officer of VIASYS Healthcare Inc., a diversified healthcare technology company, which was acquired by Cardinal Healthcare Inc. in 2007. Mr. Thurman served as a consultant to Cardinal Healthcare Inc. from the date of acquisition until 2008. From 1997 until 2001, Mr. Thurman served as Chairman and Chief Executive Officer of Strategic Reserves LLC, which provided advisory services to bio-pharmaceutical, genomic and medical device companies. From 1993 until 1997, Mr. Thurman was Chairman and Chief Executive Officer of Corning Life Sciences, Inc., and from 1984 until 1993, Mr. Thurman held various positions at Rhone-Poulenc Rorer Pharmaceuticals, Inc., a global pharmaceutical company, ultimately as its President. Mr. Thurman served as a fighter pilot in the United States Air Force, is a member of the Distinguished Flying Cross Society of America and graduated from the USAF Air Command and Staff College. Mr. Thurman holds a B.S. in Economics from Virginia Polytechnic Institute and an M.A. in Management from Webster University.
高管简历
中英对照 | 中文 | 英文- Jeff Evanson
Jeff Evanson自2018年11月起担任我们的首席商务官。Evanson先生自2018年4月起领导Scott Three Consulting，LLC担任创始人兼总裁，并于2014年9月至2018年4月担任Navigant生命科学实践的董事总经理。在加入Navigant之前，Evanson先生于2010年4月至2014年9月担任诺华制药公司爱尔康（Alcon）的Vice President兼全球药品专营权商业主管。Evanson先生担任Children&8217；s HeartLink的董事会成员，并曾于2008年至2014年担任明尼苏达州圣保罗Gillette Children&8217；s Hospital的两届董事会成员。Evanson先生在明尼苏达大学（University of Minnesota）获得工商管理硕士学位，在明尼苏达州圣保罗（St.Paul Minnesota）的圣托马斯大学（University of St.Thomas）获得化学学士学位。
Jeff Evanson,has served as Outlook Therapeutics, Inc. Chief Commercial Officer since November 2018. Mr. Evanson has led Scott Three Consulting, LLC as Founder and President since April of 2018, and from September 2014 through April 2018, served as a Managing Director in the Life Science Practice of Navigant. Prior to joining Navigant, Mr. Evanson was the Vice President and Global Commercial Head of the Pharmaceutical Franchise at Alcon, a Novartis Company from April 2010 to September 2014. Mr. Evanson serves on the board of directors of Children's HeartLink and was formerly a two-term board member of Gillette Children's Hospital in St. Paul, Minnesota, from 2008 to 2014. Mr. Evanson received his M.B.A. from the University of Minnesota, and a B.A. in Chemistry from the University of St. Thomas in St. Paul Minnesota.- Jeff Evanson自2018年11月起担任我们的首席商务官。Evanson先生自2018年4月起领导Scott Three Consulting，LLC担任创始人兼总裁，并于2014年9月至2018年4月担任Navigant生命科学实践的董事总经理。在加入Navigant之前，Evanson先生于2010年4月至2014年9月担任诺华制药公司爱尔康（Alcon）的Vice President兼全球药品专营权商业主管。Evanson先生担任Children&8217；s HeartLink的董事会成员，并曾于2008年至2014年担任明尼苏达州圣保罗Gillette Children&8217；s Hospital的两届董事会成员。Evanson先生在明尼苏达大学（University of Minnesota）获得工商管理硕士学位，在明尼苏达州圣保罗（St.Paul Minnesota）的圣托马斯大学（University of St.Thomas）获得化学学士学位。
- Jeff Evanson,has served as Outlook Therapeutics, Inc. Chief Commercial Officer since November 2018. Mr. Evanson has led Scott Three Consulting, LLC as Founder and President since April of 2018, and from September 2014 through April 2018, served as a Managing Director in the Life Science Practice of Navigant. Prior to joining Navigant, Mr. Evanson was the Vice President and Global Commercial Head of the Pharmaceutical Franchise at Alcon, a Novartis Company from April 2010 to September 2014. Mr. Evanson serves on the board of directors of Children's HeartLink and was formerly a two-term board member of Gillette Children's Hospital in St. Paul, Minnesota, from 2008 to 2014. Mr. Evanson received his M.B.A. from the University of Minnesota, and a B.A. in Chemistry from the University of St. Thomas in St. Paul Minnesota.
- C. Russell Trenary III
C. Russell Trenary III，自2021年7月起担任Outlook Therapeutics, Inc.总裁、首席执行官兼董事会成员。他最近于2020年4月至2021年7月担任InnFocus Inc.的执行顾问，2013年10月至2020年4月担任总裁兼首席执行官，包括2016年8月参天制药收购该公司。在此之前，他曾担任全球医疗器械公司G & H Orthodontics的总裁兼首席执行官，并在Advanced Medical Optics（AMO），Inc.担任过多个高级领导职位，包括白内障业务部总裁、首席营销官、美洲区总裁、公共政策执行副总裁。在此之前，Trenary先生曾在Sunrise Technologies International，Inc.担任高管职务，曾在VidaMed，Inc.担任全球销售与营销高级副总裁/官员，并在Allergan，Inc.担任过多个高级领导职务，包括高级副总裁和医学光学事业部总经理。在他的职业生涯中，他在七项收购中发挥了关键作用，并密切领导了眼部护理医疗设备领域的四项主要产品发布。Trenary先生在俄亥俄州牛津迈阿密大学获得工商管理学士学位，在密歇根州立大学获得工商管理硕士学位。
C. Russell Trenary III,has served as Outlook Therapeutics, Inc. President, Chief Executive Officer, and member of the Board of Directors, or the Board, since July 2021. He most recently was an Executive Advisor at InnFocus Inc. from April 2020 to July 2021, after serving as President & CEO from October 2013 to April 2020, including during the company's acquisition in August 2016 by Santen Pharmaceutical Co., Ltd. Prior to that, he was President and CEO of G&H Orthodontics, a global medical device company, and served in a number of senior leadership positions at Advanced Medical Optics, Inc., including as President of the cataract business unit, Chief Marketing Officer, President Americas, Executive VP Public Policy. Prior to that, Mr. Trenary held C-suite positions at Sunrise Technologies International, Inc., served as Senior Vice President, Worldwide Sales & Marketing / Officer at VidaMed, Inc. and held several senior leadership roles at Allergan, Inc., including as Senior Vice President and General Manager of the Medical Optics business unit. Over the course of his career, he has played a key role in seven acquisitions and closely led four major product launches in eye care medical devices. Mr. Trenary received a B.S. in Business Administration from Miami University, Oxford, OH and his MBA from Michigan State University.- C. Russell Trenary III，自2021年7月起担任Outlook Therapeutics, Inc.总裁、首席执行官兼董事会成员。他最近于2020年4月至2021年7月担任InnFocus Inc.的执行顾问，2013年10月至2020年4月担任总裁兼首席执行官，包括2016年8月参天制药收购该公司。在此之前，他曾担任全球医疗器械公司G & H Orthodontics的总裁兼首席执行官，并在Advanced Medical Optics（AMO），Inc.担任过多个高级领导职位，包括白内障业务部总裁、首席营销官、美洲区总裁、公共政策执行副总裁。在此之前，Trenary先生曾在Sunrise Technologies International，Inc.担任高管职务，曾在VidaMed，Inc.担任全球销售与营销高级副总裁/官员，并在Allergan，Inc.担任过多个高级领导职务，包括高级副总裁和医学光学事业部总经理。在他的职业生涯中，他在七项收购中发挥了关键作用，并密切领导了眼部护理医疗设备领域的四项主要产品发布。Trenary先生在俄亥俄州牛津迈阿密大学获得工商管理学士学位，在密歇根州立大学获得工商管理硕士学位。
- C. Russell Trenary III,has served as Outlook Therapeutics, Inc. President, Chief Executive Officer, and member of the Board of Directors, or the Board, since July 2021. He most recently was an Executive Advisor at InnFocus Inc. from April 2020 to July 2021, after serving as President & CEO from October 2013 to April 2020, including during the company's acquisition in August 2016 by Santen Pharmaceutical Co., Ltd. Prior to that, he was President and CEO of G&H Orthodontics, a global medical device company, and served in a number of senior leadership positions at Advanced Medical Optics, Inc., including as President of the cataract business unit, Chief Marketing Officer, President Americas, Executive VP Public Policy. Prior to that, Mr. Trenary held C-suite positions at Sunrise Technologies International, Inc., served as Senior Vice President, Worldwide Sales & Marketing / Officer at VidaMed, Inc. and held several senior leadership roles at Allergan, Inc., including as Senior Vice President and General Manager of the Medical Optics business unit. Over the course of his career, he has played a key role in seven acquisitions and closely led four major product launches in eye care medical devices. Mr. Trenary received a B.S. in Business Administration from Miami University, Oxford, OH and his MBA from Michigan State University.
- Lawrence A. Kenyon
Lawrence A. Kenyon，2018年8月起担任Outlook Therapeutics, Inc.董事会成员兼首席财务官，2018年8月至2021年7月担任首席执行官兼总裁，2018年6月至2018年8月担任临时首席执行官，2015年9月起担任Outlook Therapeutics, Inc.的首席财务官、财务主管兼公司秘书。在此之前，2014年2月至2015年9月，Kenyon先生担任Arno Therapeutics，Inc.的首席财务官，该公司是一家生物制药公司，专注于开发治疗癌症和其他危及生命的疾病的药物，并于2014年7月至2015年9月担任首席运营官。2011年12月至2013年3月，Kenyon先生担任Tamir Biotechnology，Inc.的临时总裁兼首席执行官、首席财务官兼秘书。Tamir Biotechnology是一家上市的生物制药公司，从事肿瘤学和抗感染疗法的开发。在此之前，2008年12月至2010年7月，Kenyon先生担任Par Pharmaceutical Companies，Inc.（一家上市的仿制药和品牌专业制药公司）财务执行副总裁，并于2009年3月起担任首席财务官。在加入Par公司之前，Kenyon先生于2007年1月至2009年2月担任Alfacell公司（简称Alfacell）的首席财务官兼秘书。在此期间，他还担任过Alfacell公司执行副总裁、首席运营官兼总裁等职务，并于2007年11月至2009年4月担任Alfacell公司董事会成员。在加入Alfacell公司之前，Kenyon先生于2000年至2006年在NeoPharm公司（一家上市的生物制药公司）担任执行副总裁、首席财务官和公司秘书。Kenyon先生在University of Wisconsin—Whitewater获得会计学学士学位，是伊利诺伊州的注册会计师。
Lawrence A. Kenyon,has served as a member of Outlook Therapeutics, Inc. Board and Chief Financial Officer since August 2018, as Chief Executive Officer and President from August 2018 to July 2021, as Interim Chief Executive Officer from June 2018 to August 2018, and as Outlook Therapeutics, Inc. Chief Financial Officer, Treasurer and Corporate Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company. Prior to March 2009, Mr. Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, from January 2007 through February 2009 and also served at various times during this period as Alfacell's Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell's board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006. Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin—Whitewater and is a Certified Public Accountant in Illinois.- Lawrence A. Kenyon，2018年8月起担任Outlook Therapeutics, Inc.董事会成员兼首席财务官，2018年8月至2021年7月担任首席执行官兼总裁，2018年6月至2018年8月担任临时首席执行官，2015年9月起担任Outlook Therapeutics, Inc.的首席财务官、财务主管兼公司秘书。在此之前，2014年2月至2015年9月，Kenyon先生担任Arno Therapeutics，Inc.的首席财务官，该公司是一家生物制药公司，专注于开发治疗癌症和其他危及生命的疾病的药物，并于2014年7月至2015年9月担任首席运营官。2011年12月至2013年3月，Kenyon先生担任Tamir Biotechnology，Inc.的临时总裁兼首席执行官、首席财务官兼秘书。Tamir Biotechnology是一家上市的生物制药公司，从事肿瘤学和抗感染疗法的开发。在此之前，2008年12月至2010年7月，Kenyon先生担任Par Pharmaceutical Companies，Inc.（一家上市的仿制药和品牌专业制药公司）财务执行副总裁，并于2009年3月起担任首席财务官。在加入Par公司之前，Kenyon先生于2007年1月至2009年2月担任Alfacell公司（简称Alfacell）的首席财务官兼秘书。在此期间，他还担任过Alfacell公司执行副总裁、首席运营官兼总裁等职务，并于2007年11月至2009年4月担任Alfacell公司董事会成员。在加入Alfacell公司之前，Kenyon先生于2000年至2006年在NeoPharm公司（一家上市的生物制药公司）担任执行副总裁、首席财务官和公司秘书。Kenyon先生在University of Wisconsin—Whitewater获得会计学学士学位，是伊利诺伊州的注册会计师。
- Lawrence A. Kenyon,has served as a member of Outlook Therapeutics, Inc. Board and Chief Financial Officer since August 2018, as Chief Executive Officer and President from August 2018 to July 2021, as Interim Chief Executive Officer from June 2018 to August 2018, and as Outlook Therapeutics, Inc. Chief Financial Officer, Treasurer and Corporate Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company. Prior to March 2009, Mr. Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, from January 2007 through February 2009 and also served at various times during this period as Alfacell's Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell's board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006. Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin—Whitewater and is a Certified Public Accountant in Illinois.